Brand Name | Status | Last Update |
---|---|---|
pylarify | New Drug Application | 2024-06-17 |
Expiration | Code | ||
---|---|---|---|
PIFLUFOLASTAT F-18, PYLARIFY, PROGENICS PHARMS INC | |||
2026-05-26 | NCE |
Code | Description |
---|---|
A9595 | Piflufolastat f-18, diagnostic, 1 millicurie |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Prostatic neoplasms | D011471 | — | C61 | 14 | 24 | 10 | 6 | 22 | 70 |
Adenocarcinoma | D000230 | — | — | — | 3 | 2 | 1 | 4 | 9 |
Recurrence | D012008 | — | — | — | — | 2 | 1 | 3 | 6 |
Neoplasms | D009369 | — | C80 | 1 | 3 | — | 1 | — | 5 |
Castration-resistant prostatic neoplasms | D064129 | — | — | — | 1 | — | 3 | — | 4 |
Urogenital neoplasms | D014565 | EFO_0003863 | D07 | — | 1 | — | 1 | — | 2 |
Neoplasms by site | D009371 | — | — | — | 1 | — | 1 | — | 2 |
Male genital diseases | D005832 | EFO_0009555 | N50.9 | — | 1 | — | 1 | — | 2 |
Prostatic diseases | D011469 | — | N42.9 | — | 1 | — | 1 | — | 2 |
Male genital neoplasms | D005834 | — | — | — | 1 | — | 1 | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Carcinoma | D002277 | — | C80.0 | 2 | 3 | — | — | 2 | 6 |
Renal cell carcinoma | D002292 | EFO_0000376 | — | 1 | 2 | — | — | 2 | 4 |
Hepatocellular carcinoma | D006528 | — | C22.0 | 1 | 2 | — | — | 1 | 4 |
Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 1 | 2 | — | — | — | 3 |
Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 1 | — | — | — | 2 |
Triple negative breast neoplasms | D064726 | — | — | — | 1 | — | — | — | 1 |
Female genital neoplasms | D005833 | — | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neurilemmoma | D009442 | EFO_0000693 | — | 1 | — | — | — | — | 1 |
Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neuroblastoma | D009447 | EFO_0000621 | — | — | — | — | — | 1 | 1 |
Neuroendocrine tumors | D018358 | EFO_1001901 | D3A.8 | — | — | — | — | 1 | 1 |
Paraganglioma | D010235 | — | — | — | — | — | — | 1 | 1 |
Carcinoid tumor | D002276 | — | D3A.00 | — | — | — | — | 1 | 1 |
Glioma | D005910 | EFO_0000520 | — | — | — | — | — | 1 | 1 |
Ovarian neoplasms | D010051 | EFO_0003893 | C56 | — | — | — | — | 1 | 1 |
Ovarian epithelial carcinoma | D000077216 | — | — | — | — | — | — | 1 | 1 |
Disease progression | D018450 | — | — | — | — | — | — | 1 | 1 |
Prostatectomy | D011468 | — | — | — | — | — | — | 1 | 1 |
Kidney neoplasms | D007680 | EFO_0003865 | C64 | — | — | — | — | 1 | 1 |
Drug common name | Piflufolastat f18 |
INN | piflufolastat (18f) |
Description | Piflufolastat F-18, sold under the brand name Pylarify among others, is a radioactive diagnostic agent used for positron emission tomography (PET) imaging. It is given by intravenous injection.
|
Classification | Small molecule |
Drug class | enzyme inhibitors: folate hydrolose (also called Prostate Specific Membrane Antigen (PSMA) or glutamate carboxypeptidase II) inhibitors |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | O=C(O)CC[C@H](NC(=O)N[C@@H](CCCCNC(=O)c1ccc([18F])nc1)C(=O)O)C(=O)O |
PDB | — |
CAS-ID | 1207181-29-0 |
RxCUI | — |
ChEMBL ID | CHEMBL4297334 |
ChEBI ID | — |
PubChem CID | 52950901 |
DrugBank | DB14805 |
UNII ID | 3934EF02T7 (ChemIDplus, GSRS) |